$CI The Cigna Group Q3 2025 Earnings Conference Call

Q3 2025 Financial Highlights

• 💡 The Cigna Group reported strong third-quarter 2025 results, with revenues of $69.7 billion and adjusted earnings per share of $7.83.
• ✅ The company reaffirmed its full-year 2025 adjusted EPS outlook of at least $29.60, demonstrating confidence in its financial commitments.

New Rebate-Free Pharmacy Model

• 🚀 Cigna introduced a transformative rebate-free model for pharmacy benefit services, replacing complex post-purchase rebates with simple upfront discounts.
• 🎯 This model aims to improve healthcare affordability and patient experience, with brand-name drug costs potentially reduced by 30% for certain plans.
• 🗓️ The new model will be adopted by Cigna Healthcare for fully insured lives by 2027 and become the standard offering for The Cigna Group by January 2028, with 50% of the business transitioning by the end of 2028.
• 🤝 It also commits to supporting independent pharmacists through fair competitive reimbursements for dispensing and clinical services.

Strategic Investments & 2026 Outlook

• ⚠️ Significant investments and transition costs are anticipated in 2026 and 2027 for recontracting, technology improvements, and process re-engineering related to the new model.
• 📈 Despite expected margin pressure in the pharmacy benefit services segment over the next two years, The Cigna Group projects overall EPS growth in 2026.
• 🔑 This growth is expected to be driven by strong performance in Cigna Healthcare and Specialty and Care Services, offsetting the temporary decline in pharmacy benefit services operating income.

Segment Performance & Growth Drivers

• 🌱 Evernorth Health Services delivered earnings in line with expectations, with Specialty and Care Services achieving 11% adjusted earnings growth.
• 🔬 A strategic investment in Shields Health Solutions further expands specialty capabilities, particularly in the provider-administered specialty market.
• 📊 Cigna Healthcare maintained solid performance, with an 84.8% medical care ratio, and expects margin expansion in its stop-loss business in 2026 due to repricing.
• ✅ Proactive renewals and extensions with major clients like the US Department of Defense, Prime Therapeutics, and Centene secure long-term partnerships through the end of the decade.